Nilotinib is named as a drug or biological intervention in 3 clinical trials in our UK, USA, India and China trial registers, 1 of which is recruiting. The lead sponsor is Novartis Pharmaceuticals. Registered phases: Phase 3 and Phase 4. Conditions studied include Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Chronic Myelogenous Leukemia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04877522 | Asciminib Roll-over Study (ClinicalTrials.gov ↗) Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
Phase 4 | Recruiting |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (ClinicalTrials.gov ↗) Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive |
Phase 3 | Active, closed |
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ClinicalTrials.gov ↗) Philadelphia Chromosome-Positive Chronic Myeloid Leukemia |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | 1 |
| Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | 1 |
| Chronic Myelogenous Leukemia | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| Register | Nilotinib trials |
|---|---|
| Clinical trials in UK | 3 |
| Clinical trials in USA | 3 |
| Clinical trials in India | 2 |
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nilotinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nilotinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.